URGN - Company ID 0001668243
The table below shows UroGen Pharma Ltd.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$45.32M | -$42.02M | -$31.73M | -$25.81M | -$24.00M | -$27.40M |
| Capital expenditure | $54.00K | $44.00K | $0.00 | $23.00K | $25.00K | $287.00K |
| Investing cash flow | -$20.69M | -$25.96M | $13.52M | $6.27M | $13.60M | $15.02M |
| Dividends paid | - | - | - |
UroGen Pharma Ltd. reported operating cash flow of -$162.44M for fiscal year 2025. That is down 67.9% from -$96.77M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $4.19M (FY 2016) to -$162.44M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $65.20M | $34.00K | $54.66M | $671.00K | $70.74M | $4.00K |